SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
FDA
FDA Gives Nod to Johnson & Johnson’s Potential Blockbuster Psoriasis Med
July 14, 2017
 · 
3 min read
BioMidwest
Why Eli Lilly Is Gouging Diabetes Drug Share From Dow’s Johnson & Johnson, Others
July 11, 2017
 · 
1 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Business
Capricor Falls as Johnson & Johnson Bails on Stem Cell Heart Med
July 7, 2017
 · 
3 min read
Deals
As Johnson & Johnson Closes $30 Billion Deal, Actelion Spinoff Is Valued at $1.54 Billion In IPO Debut
June 16, 2017
 · 
1 min read
Pharm Country
Johnson & Johnson: The Bear Case From A Bull
June 15, 2017
 · 
1 min read
Pharm Country
Johnson & Johnson Stock Just Hit an All-Time High: Here’s Why It Could Go Higher
June 12, 2017
 · 
1 min read
Johnson & Johnson Dissolves $700 Million R&D Deal With MacroGenics
Business
Johnson & Johnson Poaches Merck & Co. Exec to Run Pharma R&D
June 8, 2017
 · 
2 min read
Drug Development
Why Johnson & Johnson’s New Prostate Cancer Drug Could Spell Trouble For Pfizer
June 7, 2017
 · 
1 min read
Policy
Why Valeant CEO Thinks Johnson & Johnson Should Foot The Bill For Their Talc Defense
May 25, 2017
 · 
1 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Press Releases
Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
December 8, 2025
 · 
15 min read
Load More